12981_2019_235_MOESM1_ESM.docx (268.67 kB)
MOESM1 of Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
journal contribution
posted on 2019-08-30, 04:40 authored by Gregory Huhn, Joseph Eron, Pierre-Marie Girard, Chloe Orkin, Jean-Michel Molina, Edwin DeJesus, Romana Petrovic, Donghan Luo, Erika Landuyt, Erkki Lathouwers, Richard Nettles, Kimberley Brown, Eric WongAdditional file 1: Table S1 Baseline demographic and disease characteristics. Table S2. Summary of AEs week 48 by prior treatment experience. Table S3. Summary of AEs through week 48 by ARV regimen at baseline. Figure S1. Mean change in eGFRcystC from baseline to week 48. Figure S2. Lipid values at baseline and week 48 by demographic subgroups. Figure S3. Changes from baseline in femoral neck BMD over time based on demographic characteristics.